Long-Acting Drug Delivery Technologies and Services Market Report and Forecast 2025-2034
Description
The global long-acting drug delivery technologies and services market was valued at USD 1.06 Billion in 2024 driven by the growing prevalence of chronic diseases and continuous advancements in drug delivery technologies across the globe. It is expected to grow at a CAGR of 13.10% during the forecast period of 2025-2034 and attain a market value of USD 3.63 Billion by 2034.
Long-Acting Drug Delivery Technologies and Services Market Overview
Long-acting drug delivery technologies improve treatment effectiveness by providing sustained therapeutic effects and minimizing the frequency of doses, which enhances patient adherence to treatment plans. Key factors driving this market include the increasing incidence of chronic conditions such as diabetes and cancer, coupled with progress in biodegradable polymers and nanotechnology. Current trends, including regulatory approvals and the incorporation of digital health solutions, are influencing market development. These innovations promote growth, meeting unmet needs, and broadening applications across various therapeutic fields.
Long-Acting Drug Delivery Technologies and Services Market Growth Drivers
Rising Prevalence of Chronic Disease Boot the Market Demand
The increasing prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular disorders, is driving the demand for long-acting drug delivery technologies. According to 2023 data from the World Health Organization, non-communicable or chronic diseases were responsible for approximately 41 million deaths annually, accounting for 74% of all global fatalities. Long-acting drug delivery systems not only improve patient compliance by reducing dosing frequency but also ensure sustained therapeutic effects. Additionally, advancements in biodegradable polymers and nanotechnology, along with a growing focus on innovative treatments, are further propelling the adoption of these systems across healthcare markets.
Long-Acting Drug Delivery Technologies and Services Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Advancements in Long-Acting Drug Delivery Therapies to Enhance Market Growth
Advancements in long-acting drug delivery therapies, addressing the pressing need for improved treatment adherence and therapeutic outcomes is one of the major market trends. For instance, in May 2023, Lyndra Therapeutics' presented data on risperidone (LYN-005), a long-acting oral weekly showcasing the critical benefits of long-acting delivery systems to enhance symptom control in schizophrenia patients. The study highlighted that LYN-005 provides consistent therapeutic levels with lower peak and higher trough concentrations compared to traditional daily dosing. Such innovations in drug delivery not only aim to optimize patient adherence but also minimize side effects, ultimately shifting market dynamics toward enhanced healthcare solutions. As ongoing pivotal trials continue to validate these developments, the market for long-acting drug delivery technologies and services is poised for substantial growth in the forecast period.
Regulatory Approvals to Accelerate Long-Acting Drug Delivery Technologies and Services Market Value
The market is rapidly evolving, driven by innovative approaches that prioritize patient adherence and outcomes. Recent advancements in regulatory frameworks showcase a commitment to supporting the development of these technologies, enabling faster pathways for approval and wider accessibility. For instance, in April 2023, the US FDA approved the ABILIFY ASIMTUFII® a long-acting injectable suspension, developed collaboratively by Otsuka and Lundbeck. This is administered intramuscularly every two months for the treatment of schizophrenia and as a maintenance monotherapy for bipolar I disorder in adults. This approval not only reflects the regulatory support behind long-acting therapies but also emphasizes the growing recognition of their role in improving treatment adherence and quality of life for patients.
Integration of Nanotechnology to Meet Rising Long-Acting Drug Delivery Systems Market Demand
The integration of nanotechnology in long-acting drug delivery systems is emerging as a significant trend in the market. Nanocarriers enable targeted drug release and improved bioavailability, thus enhancing therapeutic efficacy. This technological advancement is expected to drive investments and R&D initiatives, leading to a robust expansion of the long-acting drug delivery market, catering to diverse therapeutic areas and improving patient outcomes.
Increased Adoption of Digital Health Solutions to Augment Long-Acting Drug Delivery Systems Market Size
The integration of digital health technologies in long-acting drug delivery systems is becoming increasingly prominent. These solutions improve patient monitoring and adherence, driving demand for innovative drug delivery platforms. As healthcare systems prioritize personalized medicine, digital health tools are poised to enhance the effectiveness of long-acting formulations, thereby expanding the market and catering to a broader patient demographics.
Long-Acting Drug Delivery Technologies and Services Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Share Based on End User to Witness Substantial Growth
Based on the end user the market is divided into hospitals, specialty clinics, academic and research institutes, among others. Among these, academic and research institutes are expected to dominate the market due to their commitment to developing long-acting drug delivery technologies that enhance treatment efficacy and patient compliance. They focus on innovative solutions that allow for sustained drug release, reducing the frequency of administration and improving adherence to treatment plans. By leveraging advanced delivery systems such as depot formulations, polymeric systems, and implantable devices, institutions are addressing the unique therapeutic needs of patients. This approach not only optimizes the therapeutic effects of medications but also supports the development of personalized treatment strategies that cater to individual patient requirements.
Long-Acting Drug Delivery Technologies and Services Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. Among these, North America is expected to dominate the market due to its advanced healthcare infrastructure, strong investment in R&D by pharmaceutical and biotechnology companies, and favorable regulatory frameworks. The increasing prevalence of chronic diseases is driving the demand for innovative delivery systems that enhance patient compliance. Additionally, strategic partnerships and a focus on personalized medicine further promote the development and adoption of these technologies, solidifying the region's leadership in the market.
Leading Players in the Long-Acting Drug Delivery Technologies and Services Market
The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Adare Pharma Solutions LLC
Adare Pharma Solutions LLC, founded in 2015 and headquartered in Philadelphia, Pennsylvania, USA, is a global technology-driven CDMO specializing in oral dosage forms. The company owns proprietary platforms, such as Diffucaps® and Microcaps®, which provide solutions for controlled release and taste masking to promote patient compliance. Other proprietary technologies are utilized in their long-acting drug delivery systems to solve difficult pharmaceutical formulation challenges.
Alkermes plc
Founded in 1987 and headquartered in Dublin, Ireland, Alkermes specializes in the creation of medicines for psychiatric and neurological disorders. The product portfolio with long-acting injectable formulations includes Aristada® (aripiprazole lauroxil) for schizophrenia and Vivitrol® (naltrexone for extended-release injectable suspension) to treat alcohol and opioid dependence, which serves to support their expertise in sustained-release delivery systems.
AMW GmbH
AMW GmbH, established in 2008 and based in Warngau, Germany, specializes in innovative drug delivery systems, particularly biodegradable implants and transdermal dosage forms. Their long-acting drug delivery technologies are designed to provide sustained therapeutic effects, improving patient adherence and treatment outcomes across various medical conditions.
Bostal Drug Delivery Co., Ltd.
Bostal Drug Delivery Co., Ltd., founded in 2013 and headquartered in Shanghai, China, focuses on developing advanced drug delivery systems, including long-acting injectable formulations. Their product portfolio aims to enhance the bioavailability and efficacy of therapeutics, catering to the growing demand for sustained-release medications in the global pharmaceutical market.
Other companies include Creative Biolabs Inc., ForDoz Pharma Corporation, Innocore Pharmaceuticals, Integral BioSystems LLC, Latitude Pharmaceuticals Inc., Navin Saxena Research and Technology Centre, and Samyang Holdings Biopharm Group.
Key Questions Answered in the Global Long-Acting Drug Delivery Technologies and Services Market
Long-Acting Drug Delivery Technologies and Services Market Overview
Long-acting drug delivery technologies improve treatment effectiveness by providing sustained therapeutic effects and minimizing the frequency of doses, which enhances patient adherence to treatment plans. Key factors driving this market include the increasing incidence of chronic conditions such as diabetes and cancer, coupled with progress in biodegradable polymers and nanotechnology. Current trends, including regulatory approvals and the incorporation of digital health solutions, are influencing market development. These innovations promote growth, meeting unmet needs, and broadening applications across various therapeutic fields.
Long-Acting Drug Delivery Technologies and Services Market Growth Drivers
Rising Prevalence of Chronic Disease Boot the Market Demand
The increasing prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular disorders, is driving the demand for long-acting drug delivery technologies. According to 2023 data from the World Health Organization, non-communicable or chronic diseases were responsible for approximately 41 million deaths annually, accounting for 74% of all global fatalities. Long-acting drug delivery systems not only improve patient compliance by reducing dosing frequency but also ensure sustained therapeutic effects. Additionally, advancements in biodegradable polymers and nanotechnology, along with a growing focus on innovative treatments, are further propelling the adoption of these systems across healthcare markets.
Long-Acting Drug Delivery Technologies and Services Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Advancements in Long-Acting Drug Delivery Therapies to Enhance Market Growth
Advancements in long-acting drug delivery therapies, addressing the pressing need for improved treatment adherence and therapeutic outcomes is one of the major market trends. For instance, in May 2023, Lyndra Therapeutics' presented data on risperidone (LYN-005), a long-acting oral weekly showcasing the critical benefits of long-acting delivery systems to enhance symptom control in schizophrenia patients. The study highlighted that LYN-005 provides consistent therapeutic levels with lower peak and higher trough concentrations compared to traditional daily dosing. Such innovations in drug delivery not only aim to optimize patient adherence but also minimize side effects, ultimately shifting market dynamics toward enhanced healthcare solutions. As ongoing pivotal trials continue to validate these developments, the market for long-acting drug delivery technologies and services is poised for substantial growth in the forecast period.
Regulatory Approvals to Accelerate Long-Acting Drug Delivery Technologies and Services Market Value
The market is rapidly evolving, driven by innovative approaches that prioritize patient adherence and outcomes. Recent advancements in regulatory frameworks showcase a commitment to supporting the development of these technologies, enabling faster pathways for approval and wider accessibility. For instance, in April 2023, the US FDA approved the ABILIFY ASIMTUFII® a long-acting injectable suspension, developed collaboratively by Otsuka and Lundbeck. This is administered intramuscularly every two months for the treatment of schizophrenia and as a maintenance monotherapy for bipolar I disorder in adults. This approval not only reflects the regulatory support behind long-acting therapies but also emphasizes the growing recognition of their role in improving treatment adherence and quality of life for patients.
Integration of Nanotechnology to Meet Rising Long-Acting Drug Delivery Systems Market Demand
The integration of nanotechnology in long-acting drug delivery systems is emerging as a significant trend in the market. Nanocarriers enable targeted drug release and improved bioavailability, thus enhancing therapeutic efficacy. This technological advancement is expected to drive investments and R&D initiatives, leading to a robust expansion of the long-acting drug delivery market, catering to diverse therapeutic areas and improving patient outcomes.
Increased Adoption of Digital Health Solutions to Augment Long-Acting Drug Delivery Systems Market Size
The integration of digital health technologies in long-acting drug delivery systems is becoming increasingly prominent. These solutions improve patient monitoring and adherence, driving demand for innovative drug delivery platforms. As healthcare systems prioritize personalized medicine, digital health tools are poised to enhance the effectiveness of long-acting formulations, thereby expanding the market and catering to a broader patient demographics.
Long-Acting Drug Delivery Technologies and Services Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Oral Sustained Release Systems
- Injectable Implants
- In Situ Forming Implants
- Inserts
- Wafers
- Transdermal Patches
- Microspheres
- Nanoparticles
- Others
- Oral
- Parenteral
- Transdermal
- Others
- Small Molecules
- Biologics
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Diabetes
- Ophthalmology
- Central Nervous System Disorders
- Respiratory Disorders
- Others
- Hospitals
- Specialty Clinics
- Academic & Research Institutes
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Share Based on End User to Witness Substantial Growth
Based on the end user the market is divided into hospitals, specialty clinics, academic and research institutes, among others. Among these, academic and research institutes are expected to dominate the market due to their commitment to developing long-acting drug delivery technologies that enhance treatment efficacy and patient compliance. They focus on innovative solutions that allow for sustained drug release, reducing the frequency of administration and improving adherence to treatment plans. By leveraging advanced delivery systems such as depot formulations, polymeric systems, and implantable devices, institutions are addressing the unique therapeutic needs of patients. This approach not only optimizes the therapeutic effects of medications but also supports the development of personalized treatment strategies that cater to individual patient requirements.
Long-Acting Drug Delivery Technologies and Services Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. Among these, North America is expected to dominate the market due to its advanced healthcare infrastructure, strong investment in R&D by pharmaceutical and biotechnology companies, and favorable regulatory frameworks. The increasing prevalence of chronic diseases is driving the demand for innovative delivery systems that enhance patient compliance. Additionally, strategic partnerships and a focus on personalized medicine further promote the development and adoption of these technologies, solidifying the region's leadership in the market.
Leading Players in the Long-Acting Drug Delivery Technologies and Services Market
The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Adare Pharma Solutions LLC
Adare Pharma Solutions LLC, founded in 2015 and headquartered in Philadelphia, Pennsylvania, USA, is a global technology-driven CDMO specializing in oral dosage forms. The company owns proprietary platforms, such as Diffucaps® and Microcaps®, which provide solutions for controlled release and taste masking to promote patient compliance. Other proprietary technologies are utilized in their long-acting drug delivery systems to solve difficult pharmaceutical formulation challenges.
Alkermes plc
Founded in 1987 and headquartered in Dublin, Ireland, Alkermes specializes in the creation of medicines for psychiatric and neurological disorders. The product portfolio with long-acting injectable formulations includes Aristada® (aripiprazole lauroxil) for schizophrenia and Vivitrol® (naltrexone for extended-release injectable suspension) to treat alcohol and opioid dependence, which serves to support their expertise in sustained-release delivery systems.
AMW GmbH
AMW GmbH, established in 2008 and based in Warngau, Germany, specializes in innovative drug delivery systems, particularly biodegradable implants and transdermal dosage forms. Their long-acting drug delivery technologies are designed to provide sustained therapeutic effects, improving patient adherence and treatment outcomes across various medical conditions.
Bostal Drug Delivery Co., Ltd.
Bostal Drug Delivery Co., Ltd., founded in 2013 and headquartered in Shanghai, China, focuses on developing advanced drug delivery systems, including long-acting injectable formulations. Their product portfolio aims to enhance the bioavailability and efficacy of therapeutics, catering to the growing demand for sustained-release medications in the global pharmaceutical market.
Other companies include Creative Biolabs Inc., ForDoz Pharma Corporation, Innocore Pharmaceuticals, Integral BioSystems LLC, Latitude Pharmaceuticals Inc., Navin Saxena Research and Technology Centre, and Samyang Holdings Biopharm Group.
Key Questions Answered in the Global Long-Acting Drug Delivery Technologies and Services Market
- What were the global long-acting drug delivery technologies and services market value in 2024?
- What are the global long-acting drug delivery technologies and services market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the type?
- What is the market breakup based on the route of administration?
- What is the market segmentation based on the type of molecule delivered?
- What is the market segmentation based on the application?
- What is the market breakup based on the end user?
- What are the major factors aiding the global long-acting drug delivery technologies and services market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global long-acting drug delivery technologies and services market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the global long-acting drug delivery technologies and services market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Long-Acting Drug Delivery Technologies and Services Market Overview
- 3.1 Global Long-Acting Drug Delivery Technologies and Services Market Historical Value (2018-2024)
- 3.2 Global Long-Acting Drug Delivery Technologies and Services Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Long-Acting Drug Delivery Technologies and Services Market Landscape*
- 5.1 Global Long-Acting Drug Delivery Technologies and Services Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Long-Acting Drug Delivery Technologies and Services Market: Product Landscape
- 5.2.1 Analysis By Type
- 5.2.2 Analysis By Route of Administration
- 5.2.3 Analysis By Type of Molecules Delivered
- 5.2.4 Analysis By Application
- 6 Global Long-Acting Drug Delivery Technologies and Services Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Long-Acting Drug Delivery Technologies and Services Market Segmentation (218-2034)
- 7.1 Global Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 7.1.1 Market Overview
- 7.1.2 Oral Sustained Release Systems
- 7.1.3 Injectable Implants
- 7.1.4 In Situ Forming Implants
- 7.1.5 Inserts
- 7.1.6 Wafers
- 7.1.7 Transdermal Patches
- 7.1.8 Microspheres
- 7.1.9 Nanoparticles
- 7.1.10 Others
- 7.2 Global Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Route of Administration
- 7.2.1 Market Overview
- 7.2.2 Oral
- 7.2.3 Parenteral
- 7.2.4 Transdermal
- 7.2.5 Others
- 7.3 Global Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type of Molecule Delivered
- 7.3.1 Market Overview
- 7.3.2 Small Molecules
- 7.3.3 Biologics
- 7.4 Global Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Application
- 7.4.1 Market Overview
- 7.4.2 Oncology
- 7.4.3 Cardiovascular Diseases
- 7.4.4 Infectious Diseases
- 7.4.5 Diabetes
- 7.4.6 Ophthalmology
- 7.4.7 Central Nervous System Disorders
- 7.4.8 Respiratory Disorders
- 7.4.9 Others
- 7.5 Global Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by End User
- 7.5.1 Market Overview
- 7.5.2 Hospitals
- 7.5.3 Specialty Clinics
- 7.5.4 Academic & Research Institutes
- 7.5.5 Others
- 7.6 Global Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Region
- 7.6.1 Market Overview
- 7.6.2 North America
- 7.6.3 Europe
- 7.6.4 Asia Pacific
- 7.6.5 Latin America
- 7.6.6 Middle East and Africa
- 8 North America Long-Acting Drug Delivery Technologies and Services Market (218-2034)
- 8.1 North America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 8.1.1 Market Overview
- 8.1.2 Oral Sustained Release Systems
- 8.1.3 Injectable Implants
- 8.1.4 In Situ Forming Implants
- 8.1.5 Inserts
- 8.1.6 Wafers
- 8.1.7 Transdermal Patches
- 8.1.8 Microspheres
- 8.1.9 Nanoparticles
- 8.1.10 Others
- 8.2 North America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Route of Administration
- 8.2.1 Market Overview
- 8.2.2 Oral
- 8.2.3 Parenteral
- 8.2.4 Transdermal
- 8.2.5 Others
- 8.3 North America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type of Molecule Delivered
- 8.3.1 Market Overview
- 8.3.2 Small Molecules
- 8.3.3 Biologics
- 8.4 North America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Application
- 8.4.1 Market Overview
- 8.4.2 Oncology
- 8.4.3 Cardiovascular Diseases
- 8.4.4 Infectious Diseases
- 8.4.5 Diabetes
- 8.4.6 Ophthalmology
- 8.4.7 Central Nervous System Disorders
- 8.4.8 Respiratory Disorders
- 8.4.9 Others
- 8.5 North America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by End User
- 8.5.1 Market Overview
- 8.5.2 Hospitals
- 8.5.3 Specialty Clinics
- 8.5.4 Academic & Research Institutes
- 8.5.5 Others
- 8.6 North America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Country
- 8.6.1 United States of America
- 8.6.1.1 United States of America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 8.6.2 Canada
- 8.6.2.1 Canada Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 9 Europe Long-Acting Drug Delivery Technologies and Services Market (218-2034)
- 9.1 Europe Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 9.1.1 Market Overview
- 9.1.2 Oral Sustained Release Systems
- 9.1.3 Injectable Implants
- 9.1.4 In Situ Forming Implants
- 9.1.5 Inserts
- 9.1.6 Wafers
- 9.1.7 Transdermal Patches
- 9.1.8 Microspheres
- 9.1.9 Nanoparticles
- 9.1.10 Others
- 9.2 Europe Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Route of Administration
- 9.2.1 Market Overview
- 9.2.2 Oral
- 9.2.3 Parenteral
- 9.2.4 Transdermal
- 9.2.5 Others
- 9.3 Europe Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type of Molecule Delivered
- 9.3.1 Market Overview
- 9.3.2 Small Molecules
- 9.3.3 Biologics
- 9.4 Europe Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Application
- 9.4.1 Market Overview
- 9.4.2 Oncology
- 9.4.3 Cardiovascular Diseases
- 9.4.4 Infectious Diseases
- 9.4.5 Diabetes
- 9.4.6 Ophthalmology
- 9.4.7 Central Nervous System Disorders
- 9.4.8 Respiratory Disorders
- 9.4.9 Others
- 9.5 Europe Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by End User
- 9.5.1 Market Overview
- 9.5.2 Hospitals
- 9.5.3 Specialty Clinics
- 9.5.4 Academic & Research Institutes
- 9.5.5 Others
- 9.6 Europe Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Country
- 9.6.1 United Kingdom
- 9.6.1.1 United Kingdom Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 9.6.2 Germany
- 9.6.2.1 Germany Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 9.6.3 France
- 9.6.3.1 France Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 9.6.4 Italy
- 9.6.4.1 Italy Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 9.6.5 Others
- 10 Asia Pacific Long-Acting Drug Delivery Technologies and Services Market (218-2034)
- 10.1 Asia Pacific Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 10.1.1 Market Overview
- 10.1.2 Oral Sustained Release Systems
- 10.1.3 Injectable Implants
- 10.1.4 In Situ Forming Implants
- 10.1.5 Inserts
- 10.1.6 Wafers
- 10.1.7 Transdermal Patches
- 10.1.8 Microspheres
- 10.1.9 Nanoparticles
- 10.1.10 Others
- 10.2 Asia Pacific Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Route of Administration
- 10.2.1 Market Overview
- 10.2.2 Oral
- 10.2.3 Parenteral
- 10.2.4 Transdermal
- 10.2.5 Others
- 10.3 Asia Pacific Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type of Molecule Delivered
- 10.3.1 Market Overview
- 10.3.2 Small Molecules
- 10.3.3 Biologics
- 10.4 Asia Pacific Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Application
- 10.4.1 Market Overview
- 10.4.2 Oncology
- 10.4.3 Cardiovascular Diseases
- 10.4.4 Infectious Diseases
- 10.4.5 Diabetes
- 10.4.6 Ophthalmology
- 10.4.7 Central Nervous System Disorders
- 10.4.8 Respiratory Disorders
- 10.4.9 Others
- 10.5 Asia Pacific Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by End User
- 10.5.1 Market Overview
- 10.5.2 Hospitals
- 10.5.3 Specialty Clinics
- 10.5.4 Academic & Research Institutes
- 10.5.5 Others
- 10.6 Asia Pacific Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Country
- 10.6.1 China
- 10.6.1.1 China Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 10.6.2 Japan
- 10.6.2.1 Japan Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 10.6.3 India
- 10.6.3.1 India Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 10.6.4 ASEAN
- 10.6.4.1 ASEAN Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 10.6.5 Australia
- 10.6.5.1 Australia Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 10.6.6 Others
- 11 Latin America Long-Acting Drug Delivery Technologies and Services Market (218-2034)
- 11.1 Latin America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 11.1.1 Market Overview
- 11.1.2 Oral Sustained Release Systems
- 11.1.3 Injectable Implants
- 11.1.4 In Situ Forming Implants
- 11.1.5 Inserts
- 11.1.6 Wafers
- 11.1.7 Transdermal Patches
- 11.1.8 Microspheres
- 11.1.9 Nanoparticles
- 11.1.10 Others
- 11.2 Latin America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Route of Administration
- 11.2.1 Market Overview
- 11.2.2 Oral
- 11.2.3 Parenteral
- 11.2.4 Transdermal
- 11.2.5 Others
- 11.3 Latin America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type of Molecule Delivered
- 11.3.1 Market Overview
- 11.3.2 Small Molecules
- 11.3.3 Biologics
- 11.4 Latin America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Application
- 11.4.1 Market Overview
- 11.4.2 Oncology
- 11.4.3 Cardiovascular Diseases
- 11.4.4 Infectious Diseases
- 11.4.5 Diabetes
- 11.4.6 Ophthalmology
- 11.4.7 Central Nervous System Disorders
- 11.4.8 Respiratory Disorders
- 11.4.9 Others
- 11.5 Latin America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by End User
- 11.5.1 Market Overview
- 11.5.2 Hospitals
- 11.5.3 Specialty Clinics
- 11.5.4 Academic & Research Institutes
- 11.5.5 Others
- 11.6 Latin America Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Country
- 11.6.1 Brazil
- 11.6.1.1 Brazil Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 11.6.2 Argentina
- 11.6.2.1 Argentina Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 11.6.3 Mexico
- 11.6.3.1 Mexico Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 11.6.4 Others
- 12 Middle East and Africa Long-Acting Drug Delivery Technologies and Services Market (218-2034)
- 12.1 Middle East and Africa Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Oral Sustained Release Systems
- 12.1.3 Injectable Implants
- 12.1.4 In Situ Forming Implants
- 12.1.5 Inserts
- 12.1.6 Wafers
- 12.1.7 Transdermal Patches
- 12.1.8 Microspheres
- 12.1.9 Nanoparticles
- 12.1.10 Others
- 12.2 Middle East and Africa Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Transdermal
- 12.2.5 Others
- 12.3 Middle East and Africa Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type of Molecule Delivered
- 12.3.1 Market Overview
- 12.3.2 Small Molecules
- 12.3.3 Biologics
- 12.4 Middle East and Africa Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Application
- 12.4.1 Market Overview
- 12.4.2 Oncology
- 12.4.3 Cardiovascular Diseases
- 12.4.4 Infectious Diseases
- 12.4.5 Diabetes
- 12.4.6 Ophthalmology
- 12.4.7 Central Nervous System Disorders
- 12.4.8 Respiratory Disorders
- 12.4.9 Others
- 12.5 Middle East and Africa Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by End User
- 12.5.1 Market Overview
- 12.5.2 Hospitals
- 12.5.3 Specialty Clinics
- 12.5.4 Academic & Research Institutes
- 12.5.5 Others
- 12.6 Middle East and Africa Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Country
- 12.6.1 Saudi Arabia
- 12.6.1.1 Saudi Arabia Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 12.6.2 United Arab Emirates
- 12.6.2.1 United Arab Emirates Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 12.6.3 Nigeria
- 12.6.3.1 Nigeria Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 12.6.4 South Africa
- 12.6.4.1 South Africa Long-Acting Drug Delivery Technologies and Services Market (2018-2034) by Type
- 12.6.5 Others
- 13 Patent Analysis
- 13.1 Analysis By Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Drug Class of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Strategic Initiatives
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Drug Class of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share Analysis, By Region (Top 5 Companies)
- 16.1.1 Market Share Analysis: Global
- 16.1.2 Market Share Analysis: North America
- 16.1.3 Market Share Analysis: Europe
- 16.1.4 Market Share Analysis: Asia Pacific
- 16.1.5 Market Share Analysis: Others
- 16.2 Adare Pharma Solutions LLC
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Company News and Development
- 16.2.5 Certifications
- 16.3 Alkermes plc
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Company News and Development
- 16.3.5 Certifications
- 16.4 AMW GmbH
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Company News and Development
- 16.4.5 Certifications
- 16.5 Bostal Drug Delivery Co., Ltd.
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Company News and Development
- 16.5.5 Certifications
- 16.6 Creative Biolabs Inc.
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Company News and Development
- 16.6.5 Certifications
- 16.7 ForDoz Pharma Corporation
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Company News and Development
- 16.7.5 Certifications
- 16.8 Innocore Pharmaceuticals
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Company News and Development
- 16.8.5 Certifications
- 16.9 Integral BioSystems, LLC
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Company News and Development
- 16.9.5 Certifications
- 16.10 Latitude Pharmaceuticals Inc.
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic Reach and Achievements
- 16.10.4 Company News and Development
- 16.10.5 Certifications
- 16.11 Navin Saxena Research and Technology Centre
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Company News and Development
- 16.11.5 Certifications
- 16.12 Samyang Holdings Biopharm Group
- 16.12.1 Financial Analysis
- 16.12.2 Product Portfolio
- 16.12.3 Demographic Reach and Achievements
- 16.12.4 Company News and Development
- 16.12.5 Certifications
- 17 Global Long-Acting Drug Delivery Technologies and Services Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
